Big biotech firms have beaten major drugmakers since 2010 in terms of sales growth, income, research investment and market capitalization, better placing them to deal with a changing market, according to a report from Burrill & Co. Big biotech's market cap grew 57%, to $260.6 billion, from Jan. 1, 2010, to Dec. 31, 2012, compared with a 17% hike, to $1.257 billion, for major drugmakers. "The big jump in the value of Big Biotech companies is not just a matter of investor speculation," G. Steven Burrill said. "These companies have had significant clinical and market successes that have driven their values higher."

Related Summaries